市場調査レポート

商品コード

1179529

乾癬治療薬市場：薬物クラス別、タイプ別、投与経路別：世界の機会分析および産業予測、2021-2031年

Psoriasis Therapeutics Market By Drug Class, By Type, By Route of Administration : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: 2022年09月01日 | 発行: Allied Market Research

| ページ情報: 英文 242 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,570 560,168円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,730 899,094円

レポートPDFをご利用いただけるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,506,336円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.91円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

乾癬は、皮膚細胞が通常の10倍もの速さで増殖してしまう皮膚疾患です。

このため、皮膚は白い鱗屑で覆われたデコボコの赤い斑点になります。どこにでもできますが、多くは頭皮、ひじ、ひざ、腰などにできます。乾癬は人から人へ移ることはありません。しかし、同じ家族の中で時々起こります。乾癬は通常、成人期初期に発症します。ほとんどの人は、ほんの数カ所に症状が出ます。重症の場合は、体の大部分を覆うことがあります。乾癬は治ることもあれば、一生を通じて再発することもあります。しかし、多くの治療法があります。新しい皮膚細胞の成長を遅らせるものもあれば、かゆみや皮膚の乾燥を和らげるものもあります。医師は、発疹の大きさ、体のどの部分にあるか、年齢、全身状態、その他患者さんの状態に応じて、患者さんに適した治療計画を選択します。一般的な治療法としては、ステロイドクリーム、乾燥肌用保湿剤コールタール（ローション、クリーム、フォーム、シャンプー、バスソリューションで入手できる頭皮乾癬の一般的治療法）、ビタミンDベースのクリームや軟膏、レチノイドクリームなどがあります。

乾癬治療薬の世界市場の成長を促進する主な要因としては、高齢者人口の増加、プラークおよび乾癬性関節炎の有病率の増加、有利な償還政策、生物学的製剤の処方量の増加などが挙げられます。また、市場で利用可能なさまざまな治療法に関する人々の意識の高まりが、市場の成長をさらに後押ししています。しかし、治療費の高騰に伴う投薬による健康リスクは、予測期間中の乾癬治療薬市場の成長を抑制しています。逆に、新しい生物製剤や新規パイプライン薬剤の開発の増加、未開拓の新興諸国における高い成長の可能性は、市場プレイヤーに有利な機会を提供すると予想されます。

概要
- 市場規模および予測
TNF-α阻害剤
- 主な市場動向、成長要因、機会
- 市場規模および予測：地域別
- 市場分析：国別
インターロイキンインヒビター
- 主要な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
- インターロイキン阻害剤乾癬治療薬市場：流通チャネル別
  - 病院薬局市場規模・予測：地域別
  - ドラッグストア・小売薬局市場規模・予測：地域別
  - オンラインプロバイダー市場規模推移・予測：地域別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第5章乾癬治療薬市場：タイプ別

概要
- 市場規模および予測
プラーク乾癬
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
乾癬性関節炎
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第6章乾癬治療薬市場：投与経路別

概要
- 市場規模および予測
経口
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
非経口剤
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
外用剤
- 主要な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第7章乾癬治療薬市場：地域別

概要
- 市場規模・予測
北米
- 主要動向と機会
- 北米の市場規模・予測：薬物クラス別
  - 北米のインターロイキン阻害剤別乾癬治療薬市場：流通チャネル別
- 北米の市場規模・予測：タイプ別
- 北米市場規模・予測：投与経路別
- 北米市場規模・予測：国別
  - 米国
  - カナダ
  - メキシコ
欧州
- 主要動向と機会
- 欧州の市場規模・予測：薬物クラス別
  - 欧州のインターロイキン阻害剤別乾癬治療薬市場：流通経路別
- 欧州の市場規模・予測：タイプ別
- 欧州市場規模・予測：投与経路別
- 欧州市場規模・予測：国別
  - ドイツ
  - フランス
  - 英国
  - イタリア
  - スペイン
  - その他欧州
アジア太平洋地域
- 主な動向と機会
- アジア太平洋地域の市場規模・予測：薬物クラス別
  - アジア太平洋地域のインターロイキン阻害剤別乾癬治療薬市場：流通経路別
- アジア太平洋地域の市場規模・予測：タイプ別
- アジア太平洋地域の市場規模・予測：投与経路別
- アジア太平洋地域の市場規模・予測：国別
  - 日本
  - 中国
  - インド
  - オーストラリア
  - 韓国
  - その他アジア太平洋地域
LAMEA
- 主な動向と機会
- LAMEAの乾癬治療薬市場規模・予測：薬物クラス別
  - LAMEAのインターロイキン阻害剤別乾癬治療薬市場：流通経路別
- LAMEAの市場規模・予測：タイプ別
- LAMEAの市場規模・予測：投与経路別
- LAMEAの市場規模・予測：国別
  - ブラジル
  - サウジアラビア
  - 南アフリカ共和国
  - LAMEAの残りの地域

第8章企業情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合のヒートマップ
主な発展

第9章企業プロファイル

Abbvie Inc.
Amgen Inc.
Bausch Health Companies Inc.
Eli Lilly and Company
Johnson and Johnson
LEO Pharma
Novan Inc.（EPI Health LLC）
Novartis AG
Pfizer Inc.
Viatris Inc.（Mylan NV）

図表

LIST OF TABLES

TABLE 1. GLOBAL PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 2. PSORIASIS THERAPEUTICS MARKET, FOR TNF-ALPHA INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. PSORIASIS THERAPEUTICS MARKET FOR TNF-ALPHA INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. PSORIASIS THERAPEUTICS MARKET, FOR INTERLEUKIN INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. PSORIASIS THERAPEUTICS MARKET FOR INTERLEUKIN INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. GLOBAL INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 7. PSORIASIS THERAPEUTICS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 8. PSORIASIS THERAPEUTICS MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 9. PSORIASIS THERAPEUTICS MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 10. PSORIASIS THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 11. PSORIASIS THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 13. PSORIASIS THERAPEUTICS MARKET, FOR PLAQUE PSORIASIS, BY REGION, 2021-2031 ($MILLION)
TABLE 14. PSORIASIS THERAPEUTICS MARKET FOR PLAQUE PSORIASIS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. PSORIASIS THERAPEUTICS MARKET, FOR PSORIATIC ARTHRITIS, BY REGION, 2021-2031 ($MILLION)
TABLE 16. PSORIASIS THERAPEUTICS MARKET FOR PSORIATIC ARTHRITIS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. PSORIASIS THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 18. PSORIASIS THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. GLOBAL PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 20. PSORIASIS THERAPEUTICS MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
TABLE 21. PSORIASIS THERAPEUTICS MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. PSORIASIS THERAPEUTICS MARKET, FOR PARENTERAL, BY REGION, 2021-2031 ($MILLION)
TABLE 23. PSORIASIS THERAPEUTICS MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. PSORIASIS THERAPEUTICS MARKET, FOR TOPICAL, BY REGION, 2021-2031 ($MILLION)
TABLE 25. PSORIASIS THERAPEUTICS MARKET FOR TOPICAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 26. PSORIASIS THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 32. U.S. PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 33. U.S. PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 34. U.S. PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 35. CANADA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 36. CANADA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 37. CANADA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 38. MEXICO PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 39. MEXICO PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 40. MEXICO PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 41. EUROPE PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 42. EUROPE INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 43. EUROPE PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 44. EUROPE PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 45. EUROPE PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 46. GERMANY PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 47. GERMANY PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 48. GERMANY PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 49. FRANCE PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 50. FRANCE PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 51. FRANCE PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 52. UK PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 53. UK PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 54. UK PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 55. ITALY PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 56. ITALY PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 57. ITALY PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 58. SPAIN PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 59. SPAIN PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 60. SPAIN PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 61. REST OF EUROPE PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 62. REST OF EUROPE PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 63. REST OF EUROPE PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 69. JAPAN PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 70. JAPAN PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 71. JAPAN PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 72. CHINA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 73. CHINA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 74. CHINA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 75. INDIA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 76. INDIA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 77. INDIA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 80. AUSTRALIA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 81. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 82. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 83. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 84. REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 87. LAMEA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 88. LAMEA INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 89. LAMEA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 90. LAMEA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 91. LAMEA PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 92. BRAZIL PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 93. BRAZIL PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 94. BRAZIL PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 95. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 96. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 97. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 98. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 99. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 100. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 101. REST OF LAMEA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 102. REST OF LAMEA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 103. REST OF LAMEA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 104.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 105.ABBVIE INC.: OPERATING SEGMENTS
TABLE 106.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 107.ABBVIE INC.: NET SALES,
TABLE 108.ABBVIE INC.: KEY STRATERGIES
TABLE 109.AMGEN INC.: COMPANY SNAPSHOT
TABLE 110.AMGEN INC.: OPERATING SEGMENTS
TABLE 111.AMGEN INC.: PRODUCT PORTFOLIO
TABLE 112.AMGEN INC.: NET SALES,
TABLE 113.AMGEN INC.: KEY STRATERGIES
TABLE 114.BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 115.BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS
TABLE 116.BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 117.BAUSCH HEALTH COMPANIES INC.: NET SALES,
TABLE 118.BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES
TABLE 119.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 120.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 121.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 122.ELI LILLY AND COMPANY: NET SALES,
TABLE 123.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 124.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 125.JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 126.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 127.JOHNSON AND JOHNSON: NET SALES,
TABLE 128.JOHNSON AND JOHNSON: KEY STRATERGIES
TABLE 129.LEO PHARMA: COMPANY SNAPSHOT
TABLE 130.LEO PHARMA: OPERATING SEGMENTS
TABLE 131.LEO PHARMA: PRODUCT PORTFOLIO
TABLE 132.LEO PHARMA: NET SALES,
TABLE 133.LEO PHARMA: KEY STRATERGIES
TABLE 134.NOVAN INC. (EPI HEALTH LLC): COMPANY SNAPSHOT
TABLE 135.NOVAN INC. (EPI HEALTH LLC): OPERATING SEGMENTS
TABLE 136.NOVAN INC. (EPI HEALTH LLC): PRODUCT PORTFOLIO
TABLE 137.NOVAN INC. (EPI HEALTH LLC): NET SALES,
TABLE 138.NOVAN INC. (EPI HEALTH LLC): KEY STRATERGIES
TABLE 139.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 140.NOVARTIS AG: OPERATING SEGMENTS
TABLE 141.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 142.NOVARTIS AG: NET SALES,
TABLE 143.NOVARTIS AG: KEY STRATERGIES
TABLE 144.PFIZER INC.: COMPANY SNAPSHOT
TABLE 145.PFIZER INC.: OPERATING SEGMENTS
TABLE 146.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 147.PFIZER INC.: NET SALES,
TABLE 148.PFIZER INC.: KEY STRATERGIES
TABLE 149.VIATRIS INC. (MYLAN NV): COMPANY SNAPSHOT
TABLE 150.VIATRIS INC. (MYLAN NV): OPERATING SEGMENTS
TABLE 151.VIATRIS INC. (MYLAN NV): PRODUCT PORTFOLIO
TABLE 152.VIATRIS INC. (MYLAN NV): NET SALES,
TABLE 153.VIATRIS INC. (MYLAN NV): KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.PSORIASIS THERAPEUTICS MARKET SEGMENTATION
FIGURE 2.PSORIASIS THERAPEUTICS MARKET,2021-2031
FIGURE 3.PSORIASIS THERAPEUTICS MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.PSORIASIS THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.PATENT ANALYSIS BY COMPANY
FIGURE 13.PATENT ANALYSIS BY COUNTRY
FIGURE 14.PSORIASIS THERAPEUTICS MARKET,BY DRUG CLASS,2021(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF TNF-ALPHA INHIBITORS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
FIGURE 18.PSORIASIS THERAPEUTICS MARKET,BY TYPE,2021(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF PLAQUE PSORIASIS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF PSORIATIC ARTHRITIS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
FIGURE 22.PSORIASIS THERAPEUTICS MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ORAL PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF PARENTERAL PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF TOPICAL PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
FIGURE 26.PSORIASIS THERAPEUTICS MARKET BY REGION,2021
FIGURE 27.U.S. PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 28.CANADA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 29.MEXICO PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 30.GERMANY PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 31.FRANCE PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 32.UK PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 33.ITALY PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 34.SPAIN PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 35.REST OF EUROPE PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 36.JAPAN PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 37.CHINA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 38.INDIA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 39.AUSTRALIA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 40.SOUTH KOREA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 41.REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 42.BRAZIL PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 43.SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 44.SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 45.REST OF LAMEA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 50.COMPETITIVE DASHBOARD
FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 52.ABBVIE INC..: NET SALES ,($MILLION)
FIGURE 53.AMGEN INC..: NET SALES ,($MILLION)
FIGURE 54.BAUSCH HEALTH COMPANIES INC..: NET SALES ,($MILLION)
FIGURE 55.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
FIGURE 56.JOHNSON AND JOHNSON.: NET SALES ,($MILLION)
FIGURE 57.LEO PHARMA.: NET SALES ,($MILLION)
FIGURE 58.NOVAN INC. (EPI HEALTH LLC).: NET SALES ,($MILLION)
FIGURE 59.NOVARTIS AG.: NET SALES ,($MILLION)
FIGURE 60.PFIZER INC..: NET SALES ,($MILLION)
FIGURE 61.VIATRIS INC. (MYLAN NV).: NET SALES ,($MILLION)

Product Code: A03405

Psoriasis is a skin disorder that causes skin cells to multiply up to 10 times faster than normal. This makes the skin build up into bumpy red patches covered with white scales. They can grow anywhere, but most appear on scalp, elbows, knees, and lower back. Psoriasis cannot pass from person to person. It does sometimes happen in members of the same family. Psoriasis usually appears in early adulthood. For most people, it affects just a few areas. In severe cases, it can cover large parts of the body. The patches can heal and then come back throughout a person's life. However, there are many treatments. Some slow the growth of new skin cells, and others relieve itching and dry skin. Doctor selects a treatment plan that is right for patient based on the size of rash, where it is on the body, age, overall health, and other things of patients. Common treatments include steroid creams, moisturizers for dry skin coal tar (a common treatment for scalp psoriasis available in lotions, creams, foams, shampoos, and bath solutions), vitamin D-based cream or ointments, and Retinoid creams.

Major factors that drive growth of the global psoriasis therapeutics market include increase in geriatric population, growth in prevalence of plaque and psoriatic arthritis, favorable reimbursement policies, and rise in prescription volume of biological products. In addition, rise in awareness among people regarding different treatments available in the market further propel the market growth. However, health risks posed, owing to medication along with high costs of therapies restrain growth of the psoriasis therapeutics market during the forecast period. Conversely, increase in development of new biologics and novel pipeline drugs and high growth potential in untapped emerging countries are anticipated to provide lucrative opportunities to the market players.

The psoriasis therapeutics market is segmented on the basis of drug class, type, route of administration, end user, and region. According to drug class, the market is categorized into TNF-alpha inhibitors, interleukin inhibitors, and others. Interleukin inhibitors further segmented by distribution channel, including hospital pharmacies, drug stores & retail pharmacies, and online providers. On the basis of type, it is divided into plaque psoriasis, psoriatic arthritis, and others. On the basis of route of administration, it is classified into oral, topical, and parenteral. Furthermore, regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include: AbbVie Inc., Amgen Inc., Bausch Health Companies Inc, Eli Lilly and Company, Johnson & Johnson (J&J), Leo Pharma A/S, Novan, Inc., Novartis AG, Pfizer Inc., and Viatris Inc.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the psoriasis therapeutics market analysis from 2021 to 2031 to identify the prevailing psoriasis therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the psoriasis therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global psoriasis therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

TNF-alpha Inhibitors
Interleukin Inhibitors
- Distribution Channel
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
Others

By Type

Plaque Psoriasis
Psoriatic Arthritis
Others

By Route of Administration

Oral
Parenteral
Topical

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
Asia-Pacific
- Rest Of Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
Key Market Players
- Abbvie Inc.
- Amgen Inc.
- Bausch Health Companies Inc.
- Eli Lilly and Company
- Johnson and Johnson
- LEO Pharma
- Novan Inc. (EPI Health LLC)
- Novartis AG
- Pfizer Inc.
- Viatris Inc. (Mylan NV)

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape

CHAPTER 4: PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS

4.1 Overview
- 4.1.1 Market size and forecast
4.2 TNF-alpha Inhibitors
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Interleukin Inhibitors
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.3.4 Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
  - 4.3.4.1 Hospital Pharmacies Market size and forecast, by region
  - 4.3.4.2 Drug Stores and Retail Pharmacies Market size and forecast, by region
  - 4.3.4.3 Online Providers Market size and forecast, by region
4.4 Others
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country

CHAPTER 5: PSORIASIS THERAPEUTICS MARKET, BY TYPE

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Plaque Psoriasis
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Psoriatic Arthritis
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Others
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country

CHAPTER 6: PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Oral
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Parenteral
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Topical
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: PSORIASIS THERAPEUTICS MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Drug Class
  - 7.2.2.1 North America Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
- 7.2.3 North America Market size and forecast, by Type
- 7.2.4 North America Market size and forecast, by Route of Administration
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Drug Class
  - 7.2.5.1.2 Market size and forecast, by Type
  - 7.2.5.1.3 Market size and forecast, by Route of Administration
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Drug Class
  - 7.2.5.2.2 Market size and forecast, by Type
  - 7.2.5.2.3 Market size and forecast, by Route of Administration
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Drug Class
  - 7.2.5.3.2 Market size and forecast, by Type
  - 7.2.5.3.3 Market size and forecast, by Route of Administration
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Drug Class
  - 7.3.2.1 Europe Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
- 7.3.3 Europe Market size and forecast, by Type
- 7.3.4 Europe Market size and forecast, by Route of Administration
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Drug Class
  - 7.3.5.1.2 Market size and forecast, by Type
  - 7.3.5.1.3 Market size and forecast, by Route of Administration
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Drug Class
  - 7.3.5.2.2 Market size and forecast, by Type
  - 7.3.5.2.3 Market size and forecast, by Route of Administration
  - 7.3.5.3 UK
  - 7.3.5.3.1 Market size and forecast, by Drug Class
  - 7.3.5.3.2 Market size and forecast, by Type
  - 7.3.5.3.3 Market size and forecast, by Route of Administration
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Drug Class
  - 7.3.5.4.2 Market size and forecast, by Type
  - 7.3.5.4.3 Market size and forecast, by Route of Administration
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Drug Class
  - 7.3.5.5.2 Market size and forecast, by Type
  - 7.3.5.5.3 Market size and forecast, by Route of Administration
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Drug Class
  - 7.3.5.6.2 Market size and forecast, by Type
  - 7.3.5.6.3 Market size and forecast, by Route of Administration
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
  - 7.4.2.1 Asia-Pacific Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
- 7.4.3 Asia-Pacific Market size and forecast, by Type
- 7.4.4 Asia-Pacific Market size and forecast, by Route of Administration
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Drug Class
  - 7.4.5.1.2 Market size and forecast, by Type
  - 7.4.5.1.3 Market size and forecast, by Route of Administration
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Drug Class
  - 7.4.5.2.2 Market size and forecast, by Type
  - 7.4.5.2.3 Market size and forecast, by Route of Administration
  - 7.4.5.3 India
  - 7.4.5.3.1 Market size and forecast, by Drug Class
  - 7.4.5.3.2 Market size and forecast, by Type
  - 7.4.5.3.3 Market size and forecast, by Route of Administration
  - 7.4.5.4 Australia
  - 7.4.5.4.1 Market size and forecast, by Drug Class
  - 7.4.5.4.2 Market size and forecast, by Type
  - 7.4.5.4.3 Market size and forecast, by Route of Administration
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Drug Class
  - 7.4.5.5.2 Market size and forecast, by Type
  - 7.4.5.5.3 Market size and forecast, by Route of Administration
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Drug Class
  - 7.4.5.6.2 Market size and forecast, by Type
  - 7.4.5.6.3 Market size and forecast, by Route of Administration
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Drug Class
  - 7.5.2.1 LAMEA Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
- 7.5.3 LAMEA Market size and forecast, by Type
- 7.5.4 LAMEA Market size and forecast, by Route of Administration
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Drug Class
  - 7.5.5.1.2 Market size and forecast, by Type
  - 7.5.5.1.3 Market size and forecast, by Route of Administration
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Drug Class
  - 7.5.5.2.2 Market size and forecast, by Type
  - 7.5.5.2.3 Market size and forecast, by Route of Administration
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Drug Class
  - 7.5.5.3.2 Market size and forecast, by Type
  - 7.5.5.3.3 Market size and forecast, by Route of Administration
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Drug Class
  - 7.5.5.4.2 Market size and forecast, by Type
  - 7.5.5.4.3 Market size and forecast, by Route of Administration

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Abbvie Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Amgen Inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Bausch Health Companies Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Eli Lilly and Company
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Johnson and Johnson
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 LEO Pharma
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Novan Inc. (EPI Health LLC)
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Novartis AG
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Pfizer Inc.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Viatris Inc. (Mylan NV)
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments

乾癬治療薬市場：薬物クラス別、タイプ別、投与経路別：世界の機会分析および産業予測、2021-2031年

Psoriasis Therapeutics Market By Drug Class, By Type, By Route of Administration : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章乾癬治療薬市場：薬効分類別

第5章乾癬治療薬市場：タイプ別

第6章乾癬治療薬市場：投与経路別

第7章乾癬治療薬市場：地域別

第8章企業情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS

CHAPTER 5: PSORIASIS THERAPEUTICS MARKET, BY TYPE

CHAPTER 6: PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

CHAPTER 7: PSORIASIS THERAPEUTICS MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

乾癬治療薬市場：薬物クラス別、タイプ別、投与経路別：世界の機会分析および産業予測、2021-2031年

Psoriasis Therapeutics Market By Drug Class, By Type, By Route of Administration : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

第4章 乾癬治療薬市場：薬効分類別

第5章 乾癬治療薬市場：タイプ別

第6章 乾癬治療薬市場：投与経路別

第7章 乾癬治療薬市場：地域別

第8章 企業情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS

CHAPTER 5: PSORIASIS THERAPEUTICS MARKET, BY TYPE

CHAPTER 6: PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

CHAPTER 7: PSORIASIS THERAPEUTICS MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章乾癬治療薬市場：薬効分類別

第5章乾癬治療薬市場：タイプ別

第6章乾癬治療薬市場：投与経路別

第7章乾癬治療薬市場：地域別

第8章企業情勢

第9章企業プロファイル